

# Identification of Proline Residues in or near the Transmembrane Helices of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) That Are Important for Transport Activity and Substrate Specificity

Zhanglin Ni,<sup>†</sup> Zsolt Bikadi,<sup>§</sup> Diana L. Shuster,<sup>†</sup> Chunsheng Zhao,<sup>‡</sup> Mark F. Rosenberg,<sup>||</sup> and Qingcheng Mao<sup>\*,†</sup>


<sup>†</sup>Department of Pharmaceutics and <sup>‡</sup>Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington 98195-7610, United States

<sup>§</sup>Virtua Drug Ltd., Budapest, Hungary

<sup>||</sup>Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, United Kingdom

## Supporting Information

**ABSTRACT:** The human breast cancer resistance protein (BCRP/ABCG2) confers multidrug resistance and mediates the active efflux of drugs and xenobiotics. BCRP contains one nucleotide-binding domain (NBD) followed by one membrane-spanning domain (MSD). We investigated whether prolines in or near the transmembrane helices are essential for BCRP function. Six proline residues were substituted with alanine individually, and the mutants were stably expressed in Flp-In<sup>TM</sup>-293 cells at levels comparable to that of wild-type BCRP and predominantly localized on the plasma membrane of the cells. While P392A showed a significant reduction (35–50%) in the efflux activity of mitoxantrone, BODIPY-prazosin, and Hoechst 33342, P485A exhibited a significant decrease of approximately 70% in the efflux activity of only BODIPY-prazosin. Other mutants had no significant changes in the efflux activities of these substrates. Drug resistance profiles of the cells expressing the mutants correlated well with the efflux data. ATPase activity was not substantially affected for P392A or P485A compared to that of wild-type BCRP. These results strongly suggest Pro<sup>392</sup> and Pro<sup>485</sup> are important in determining the overall transport activity and substrate selectivity of BCRP, respectively. Prazosin differentially affected the binding of SD3, a conformation-sensitive antibody, to wild-type BCRP, P392A, or P485A in a concentration-dependent manner. In contrast, mitoxantrone had no significant effect on SD3 binding. Homology modeling indicates that Pro<sup>392</sup> may play an important role in the communication between the MSD and NBD as it is predicted to be located at the interface between the two functional domains, and Pro<sup>485</sup> induces flexible hinges that may be essential for the broad substrate specificity of BCRP.



The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-binding cassette (ABC) efflux transporter that confers resistance to chemotherapeutic agents such as mitoxantrone and SN-38.<sup>1–4</sup> BCRP also actively transports a large variety of nonchemotherapeutic drugs and xenobiotics.<sup>1,5</sup> BCRP is strongly expressed in stem cells,<sup>6</sup> the liver canalicular membrane,<sup>7</sup> the apical membrane of the small intestine and colon epithelium,<sup>7</sup> the brain microvessel endothelium,<sup>8</sup> and the apical membrane of placental syncytiotrophoblasts.<sup>7</sup> Therefore, BCRP plays an important role in drug disposition and tissue protection.<sup>1,2</sup>

BCRP is a half-transporter comprising one N-terminal nucleotide-binding domain (NBD) followed by one membrane-spanning domain (MSD).<sup>1,5</sup> BCRP is believed to form a homodimer or homooligomer, and its function depends on homodimerization.<sup>9–12</sup> The MSD of BCRP contains six transmembrane (TM)  $\alpha$ -helices.<sup>13</sup> To date, little is known about the structure of BCRP or the mechanism of its ability to transport a broad range of substrates. Recently, we have

determined the projection structures of BCRP at moderate resolutions (5–7 Å) and demonstrated that BCRP undergoes significant conformational changes upon mitoxantrone binding.<sup>14</sup> Site-directed mutagenesis studies by various laboratories have shown that some charged or polar residues within or near TM helices are important in determining the overall transport activity and substrate specificity of BCRP.<sup>15–20</sup> However, how exactly BCRP recognizes and transports a wide spectrum of structurally unrelated substrates remains largely unknown.

Proline residues are found more frequently in TM  $\alpha$ -helices of polytopic membrane proteins than in  $\alpha$ -helices of soluble proteins and have been suggested to play structural and/or dynamic roles in membrane proteins.<sup>21,22</sup> Proline cannot form normal backbone hydrogen bonds in the helix as proline lacks an amide hydrogen. The bulky proline may also cause a steric

Received: April 15, 2011

Revised: August 17, 2011

Published: August 22, 2011



constraint on the conformation of adjacent residues. These two factors can potentially distort the regular structure of TM helices by introducing a kink between the segments adjacent to the proline. This can induce flexibility in the region by introducing a molecular switch or hinge.<sup>23</sup> Thus, proline residues in or near TM helices can have important structural (e.g., facilitating helix packing<sup>24</sup>) and/or functional (e.g., involved in ligand binding,<sup>25</sup> conformational changes,<sup>26</sup> or substrate selectivity<sup>27,28</sup>) roles in membrane proteins, including transport proteins.

There are six proline residues in or near TM helices of BCRP, namely, Pro<sup>392</sup>, Pro<sup>480</sup>, Pro<sup>485</sup>, Pro<sup>501</sup>, Pro<sup>574</sup>, and Pro<sup>602</sup> (Figure 1), which are the focus of this study. Pro<sup>602</sup> is located in


in the presence of substrates. A homology model of BCRP was used to assess the potential structural mechanism.

## EXPERIMENTAL PROCEDURES

**Materials.** Fumitremorgin C (FTC) was obtained from the National Cancer Institute (Bethesda, MD). BODIPY FL-prazosin was from Molecular Probes (Eugene, OR). Mitoxantrone hydrochloride (MX), doxorubicin hydrochloride (Dox), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Sigma (St. Louis, MO). SN-38 was from TOCRIS Bioscience (Ellisville, MO). Rhodamine 123 (Rho123) was from MP Biomedicals (Irvine, CA). HPLC-grade DMSO was from Fisher Scientific (Waltham, MA). Fetal bovine serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA). PBS, DMEM, 4',6-diamidino-2-phenylindole (DAPI), Hoechst 33342, and Alexa-Fluor 488-conjugated goat anti-mouse IgG (H + L) (Fab')<sub>2</sub> fragment were from Invitrogen (Carlsbad, CA). FuGENE HD transfection reagent and protease inhibitor cocktail tablets were from Roche Applied Science (Indianapolis, IN). All restriction enzymes were from New England Biolabs (Beverly, MA). Primers used for PCR were synthesized by Operon (Huntsville, AL). The BCRP-specific mouse monoclonal antibody (mAb) BXP-21 was from Kamiya Biomedical Co. (Seattle, WA). The monoclonal goat anti-mouse HRP-conjugated antibody was from Bio-Rad (Hercules, CA). The phycoerythrin-conjugated anti-BCRP mAb SD3 (catalog no. 12-8888-73) and phycoerythrin-conjugated negative control antibody IgG2b were from eBioscience (San Diego, CA). Fluoromount G was from Southern Biotech (Birmingham, AL). The pcDNA3.1 plasmid containing full-length wild-type human BCRP cDNA was kindly provided by S. E. Bates (National Cancer Institute). Flp-In<sup>TM</sup>-293 cells, the pcDNA5/FRT and pOG44 plasmids, zeocin, and hygromycin B were from Invitrogen. All other reagents and chemicals were of the highest purity available commercially.


**Site-Directed Mutagenesis.** Full-length wild-type human BCRP cDNA in pcDNA3.1 was subcloned into pcDNA5/FRT.<sup>15</sup> The pcDNA5/FRT plasmid containing full-length human BCRP cDNA was used as a template to generate all the BCRP mutants using PCR mutagenesis as previously described.<sup>15</sup> The following forward primers were used for mutagenesis: P392A (5'-AAC TTG CTG GGT AAT GCC CAG GCC TCT ATA GCT C-3'), P480A (5'-CTG TTA TCT GAT TTA TTA GCC ATG AGG ATG TTA CCA AG-3'), P485A (5'-CCC ATG AGG ATG TTA GCA AGT ATT ATA TTT ACC TGT ATA G-3'), P501A (5'-CAT GTT AGG ATT GAA GGC AAA GGC AGA TGC CTT C-3'), P574A (5'-CAG TAC TTC AGC ATT GCA CGA TAT GGA TTT ACG-3'), and P623A (5'-GGC ATC GAT CTC TCA GCC TGG GGC TTG TGG AAG AAT-3'). The reverse primers were complementary to the respective forward primers. All the mutants were confirmed by DNA sequencing, and the entire BCRP cDNA in each construct was also sequenced to make sure that no additional mutations were introduced during PCR.

**Generation of Flp-In<sup>TM</sup>-293 Cells Stably Expressing Wild-Type BCRP and Proline Mutants.** One microgram of the pcDNA5/FRT plasmid containing wild-type or mutant BCRP cDNA or the empty vector was transfected into Flp-In<sup>TM</sup>-293 cells in combination with 2  $\mu$ g of pOG44 using the FuGENE HD transfection, according to the manufacturer's instructions. After being recovered, cells were selected in 125  $\mu$ g/mL hygromycin for approximately 3–4 weeks. The cells



**Figure 1.** Human BCRP topology (A) and sequence alignment (B). (A) The boundary of TM helices is based on the experimentally determined membrane topology of BCRP, and only the MSD is shown. Proline residues analyzed in this study are circled and indicated with amino acid positions. (B) The human BCRP amino acid sequence in the TM helices was aligned with the corresponding sequences of BCRP homologues and orthologs using Clustal W. Proline residues analyzed in this study are highlighted.

the middle of the large extracellular loop connecting TM5 and TM6 and is far from the TM boundaries. In analysis of previous studies of P-gp and MRP1, we noted that mutation of proline residues in the intracellular or extracellular loops connecting TM helices had either no effect (such as those in P-gp<sup>27</sup>) or a moderate effect (such as some of those in MRP1<sup>29,30</sup>) on transport activity, with only one exception, Pro<sup>1150</sup> in MRP1, which is located in the intracellular loop connecting TM15 and TM16.<sup>28,31</sup> Mutation of Pro<sup>1150</sup> of MRP1 substantially increased the rate of transport of 17 $\beta$ -estradiol-17- $\beta$ -D-glucuronide and methotrexate but had no effect on or reduced the rate of transport of other organic anions,<sup>28</sup> possibly because of an alteration in the role of the intracellular loop as a coupling helix between the MSD and the NBD of MRP1, which is not the case for Pro<sup>602</sup> in BCRP.<sup>31</sup> We therefore did not include Pro<sup>602</sup> in this study. We investigated the functional importance of the six prolines in or near TM helices for BCRP activity. These prolines were replaced with alanine individually by site-directed mutagenesis. The BCRP mutants were expressed in Flp-In<sup>TM</sup>-293 cells by stable transfection and characterized with respect to their ability to transport drugs, drug resistance, basal ATPase activity, and binding affinity for the SD3 monoclonal antibody



**Figure 2.** Immunoblotting analysis of the expression levels of wild-type and mutant BCRP. The protein expression levels of wild-type and mutant BCRP in stably transfected Flp-In<sup>TM</sup>-293 cells were determined by immunoblotting, densitometric analysis of the blots, and normalization to an internal standard. (A) Immunoblot of whole cell lysates for wild-type and mutant BCRP. Each lane was loaded with 20  $\mu$ g of protein. (B) Protein expression levels of the mutants relative to that of wild-type BCRP (100%) in whole cell lysates. Shown are means  $\pm$  SD of three experiments. (C) Immunoblot of plasma membrane preparations for wild-type and mutant BCRP. Each lane was loaded with 5  $\mu$ g of protein. (D) Protein expression levels of P392A and P485A relative to that of wild-type BCRP (100%) in the plasma membrane samples. Shown are means  $\pm$  SD of three experiments.

expressing wild-type or mutant BCRP were then maintained in complete DMEM containing 10% FBS, L-glutamine, and 125  $\mu$ g/mL hygromycin for subsequent experiments.

**Immunoblotting, Confocal Microscopy, and Cell Surface Expression of BCRP.** Immunoblotting, confocal microscopy, and detection of cell surface expression of BCRP were performed exactly the same as previously described.<sup>15,17</sup> For the immunoblotting assay and confocal microscopy study, BCRP-specific mAb BXP-21 was used. The 5D3 mAb was used for cell surface detection of BCRP (20  $\mu$ L of the 5D3 antibody incubated with approximately  $5 \times 10^5$  cells). Human  $\beta$ -actin was detected as an internal standard during immunoblotting of whole cell lysates. Relative protein expression levels of wild-type and mutant BCRP were determined by densitometric analysis and normalization to  $\beta$ -actin as previously described.<sup>15,17</sup>

**Plasma Membrane Preparation.** Plasma membranes were prepared as previously described.<sup>15,17</sup> BCRP expression in the plasma membrane samples was assessed by immunoblotting using mAb BXP-21. The human plasma membrane protein  $\text{Na}^+/\text{K}^+$ -ATPase was detected as an internal standard. Relative protein expression levels of wild-type and mutant BCRP were determined by densitometric analysis and normalization to  $\text{Na}^+/\text{K}^+$ -ATPase as previously described.<sup>15,17</sup>

**Flow Cytometric Efflux Assay.** Flow cytometric efflux assays were performed essentially as previously described.<sup>15</sup> Briefly, cells were first incubated with 10  $\mu$ M MX, 500 nM BODIPY-prazosin, or 0.05  $\mu$ g/mL Hoechst 33342, in the presence and absence of 10  $\mu$ M FTC for 30 min at 37  $^\circ\text{C}$ . Cells were then washed and resuspended in 1 mL of fluorescent compound-free incubation buffer with or without 10  $\mu$ M FTC, and the incubation was continued for 1 h at 37  $^\circ\text{C}$ . Cells were

washed, and intracellular fluorescence was measured as previously described.<sup>15</sup> Cells in medium containing a fluorescent compound alone and in medium containing the fluorescent compound and FTC generated the efflux and FTC-efflux histograms, respectively. The difference ( $\Delta F$ ) in median fluorescence between the FTC-efflux histogram and the respective efflux histogram was used as a measure of FTC-inhibitable efflux activity of wild-type and mutant BCRP. The statistical significance of the differences in efflux activity between wild-type and mutant BCRP was analyzed using a Student's *t* test. A difference with a *p* value of  $<0.05$  was considered statistically significant.

**Cytotoxicity Assay.** Drug resistance profiles of Flp-In<sup>TM</sup>-293 cells expressing wild-type and mutant BCRP and the vector control cells were determined using the MTT microtiter plate assay as previously described.<sup>15</sup>

**Vanadate-Sensitive ATPase Activity.** Vanadate-sensitive ATPase activities of wild-type and mutant BCRP were determined by measuring the liberation of inorganic phosphate from MgATP as previously described.<sup>15</sup>

**Concentration-Dependent Effects of BCRP Substrates on 5D3 Binding to Wild-Type and Mutant BCRP.** The effects of BCRP substrates, prazosin and MX, on the binding of 5D3 to wild-type and mutant BCRP were determined as previously described.<sup>15</sup> Briefly,  $\sim 5 \times 10^5$  cells were incubated in the presence or absence of various concentrations of prazosin (0–40  $\mu$ M) or MX (0–80  $\mu$ M) for 5 min at 37  $^\circ\text{C}$  followed by the addition of the 5D3 or IgG2b antibody (20  $\mu$ L each), and incubation was continued for 30 min at 37  $^\circ\text{C}$ . Cells were then washed and analyzed using flow cytometry as previously described.<sup>15</sup> The concentration-dependent effects of substrates on the binding of 5D3 to BCRP were determined by the



differences ( $\Delta F/F_0$ ) in phycoerythrin fluorescence between the cells incubated with SD3 in the presence of a substrate (prozosin or MX) and SD3 alone ( $F_0$ ). In preliminary experiments, we found that MX alone up to 80  $\mu$ M did not have any effect on the phycoerythrin fluorescence of phycoerythrin-conjugated antibodies.


**Homology Modeling.** We have previously built a homology model of BCRP based on the recently published crystal structure of mouse P-gp, which represents the substrate-bound and nucleotide-free inward-facing form of BCRP.<sup>14</sup> We used this model to assess potential structural roles of proline residues in BCRP. To explore the potential conformational flexibility of TM3 that contains Pro<sup>480</sup> and Pro<sup>485</sup> in a PXXXXP helix motif, we tested several kink conformations in our homology model, based on X-ray crystal structures of TM helices that contain prolines at both N<sub>α</sub><sup>end</sup> and N<sub>α</sub><sup>5</sup> positions from a TM helix database.<sup>22</sup> Two PXXXXP TM helix motifs, PAFVAP (PDB entry 1EHK1) and PHAAVP (PDB entry 1EHK2), found in PDB entry 1EHK<sup>32</sup> were selected for modeling of the potential alternate helix conformations of TM3. We also tested a similar GXXXXP motif found in PDB entry 2RCR.<sup>33</sup> The BCRP models with alternate TM3 conformations were generated as follows. First, three-dimensional coordinates of the proline-containing TM helices were cut from the original crystal structures. Second, these TM helices were structurally aligned to the N-terminal half of TM3 in the original BCRP model as templates. Finally, new models of BCRP were built using its own homology model<sup>14</sup> as a template except for the TM3 region where the kink conformations of the selected TM helices were used as the structural templates. The BCRP models were built using Modeler version 9.8<sup>34</sup> exactly the same as previously described.<sup>14</sup>

## RESULTS

**Expression of Wild-Type BCRP and Proline Mutants in Flp-In<sup>TM</sup>-293 Cells.** According to the membrane topology of BCRP we determined,<sup>13</sup> six proline residues, namely, Pro<sup>392</sup>, Pro<sup>480</sup>, Pro<sup>485</sup>, Pro<sup>501</sup>, Pro<sup>574</sup>, and Pro<sup>623</sup>, exist in the TM helices or no more than five amino acid residues outside of the TM boundaries (Figure 1A). These proline residues are strongly conserved in the human, mouse, rat, monkey, bovine, and porcine orthologs of BCRP (Figure 1B). To investigate the importance of the six proline residues in BCRP transport function, we substituted the six proline residues with alanine individually. Alanine was used because it has been shown to possess the highest helix propensity compared to those of other amino acids,<sup>35</sup> and therefore, alanine substitutions of proline may result in mutants with potentially minimal effects on BCRP stability and structural integrity. Also, substitution with alanine or any other amino acids would similarly eliminate the molecular hinges potentially introduced by a proline into TM helices. Flp-In<sup>TM</sup>-293 cell lines stably expressing wild-type BCRP and the proline mutants were generated by cotransfection of pcDNA5/FRT expression vectors and pOG44 and subsequent selection with hygromycin. The resultant cell lines expressed the mutants at levels comparable to that of wild-type BCRP as determined by immunoblotting of whole cell lysates using  $\beta$ -actin as an internal standard (Figure 2A,B).


**Plasma Membrane Localization and Cell Surface Expression of Wild-Type and Mutant BCRP in Flp-In<sup>TM</sup>-293 Cells.** To determine if the proline mutations affect the proper folding and trafficking of BCRP to the plasma

membrane, Flp-In<sup>TM</sup>-293 cells stably expressing wild-type and mutant BCRP were analyzed by immunofluorescence confocal microscopy with BCRP-specific mAb BXP-21. Wild-type BCRP and all six proline mutants were observed to be predominantly localized on the plasma membrane (Figure 3A), suggesting that



**Figure 3.** Confocal microscopy analysis and cell surface expression of Flp-In<sup>TM</sup>-293 cells stably expressing wild-type and mutant BCRP. (A) The cellular localization of wild-type and mutant BCRP in Flp-In<sup>TM</sup>-293 cells (green) was determined by immunofluorescence confocal microscopy using BCRP-specific mAb BXP-21. Cell nuclei were stained with DAPI and are colored red. (B) Expression of wild-type and mutant BCRP on the cell surface of stably transfected Flp-In<sup>TM</sup>-293 cells was detected using the SD3 monoclonal antibody. Representative flow cytometry histograms showing cell surface expression of wild-type and mutant BCRP are presented. The red and blue peaks represent the phycoerythrin fluorescence associated with cells treated with the IgG2b negative control and the SD3 antibodies, respectively. No surface expression of BCRP was detected in the pcDNA5 vector control cells.

the mutants retained proper folding and maturation as wild-type BCRP. To further verify cell surface expression of these mutants, cells were incubated with the phycoerythrin-conjugated BCRP-specific mAb SD3 or the IgG2b negative control antibody. Cell surface expression of BCRP was demonstrated by determining the differences in cell-associated phycoerythrin fluorescence between the SD3 and IgG2b incubations using flow cytometry. As expected, the pcDNA5 vector control cells did not exhibit any cell surface expression of BCRP (Figure 3B). Wild-type and mutant BCRP all exhibited significant cell surface expression. The estimated relative cell surface expression levels of wild-type and mutant BCRP based on the differences in median fluorescence between SD3 and IgG2b control incubations were  $100 \pm 22$ ,  $108 \pm 4$ ,  $89 \pm 1$ ,  $139 \pm 32$ ,  $75 \pm 16$ ,  $76 \pm 9$ , and  $114 \pm 0.7\%$  for three independent determinations for wild-type BCRP, P392A, P480A, P485A, P501A, P574A, and P623A, respectively. Overall, these results were consistent with the immunoblotting data (Figure 2), with a generally <25% difference between wild-type and mutant BCRP. The SD3 fluorescence associated with P485A was increased by 39% compared to that of wild-type BCRP, but the difference was not statistically significant ( $p > 0.05$  by a



**Figure 4.** FTC-inhibitable efflux activities of Flp-In<sup>TM</sup>-293 cells stably expressing wild-type and mutant BCRP. Three substrates, mitoxantrone (A), BODIPY-prazosin (B), and Hoechst 33342 (C), were used. The efflux activities were expressed as the differences in median fluorescence ( $\Delta F$ ) between the FTC-efflux and efflux histograms. Shown are means  $\pm$  SD of three experiments. Differences in efflux activities between wild-type and mutant BCRP are statistically significant (\* $p < 0.05$  by a Student's  $t$  test). The pcDNAs vector control, wild-type BCRP, P392A, P480A, P485A, P501A, P574A, and P623A are indicated by P, WT, 392, 480, 485, 501, 574, and 623, respectively. Because the expression levels of wild-type and mutant BCRP were comparable, we did not normalize the efflux activity data to BCRP protein expression.

**Table 1. Drug Resistance Profile of Wild-Type and Mutant BCRP<sup>a</sup>**

	MX		SN-38		Dox		Rho123	
	IC <sub>50</sub> (nM)	RR	IC <sub>50</sub> (nM)	RR	IC <sub>50</sub> (nM)	RR	IC <sub>50</sub> (nM)	RR
pcDNAs/FRT	5.6 $\pm$ 0.8	—	1.7 $\pm$ 0.1	—	33.1 $\pm$ 2.2	—	4218 $\pm$ 400.0	—
wild-type BCRP	51.5 $\pm$ 8.5	9.2	30.3 $\pm$ 2.0	17.8	40.9 $\pm$ 6.7	1.2	4446 $\pm$ 261.5	1.1
P392A	24.6 $\pm$ 3.8	4.4*	13.1 $\pm$ 1.0	7.7*	34.8 $\pm$ 1.7	1.1	5326 $\pm$ 414.1	1.3
P480A	69.4 $\pm$ 10.5	12.4	37.8 $\pm$ 1.5	22.2	29.0 $\pm$ 4.0	0.9	5107 $\pm$ 272.7	1.2
P485A	38.5 $\pm$ 7.0	6.9	15.9 $\pm$ 2.6	9.4*	41.8 $\pm$ 5.3	1.3	3237 $\pm$ 199.5	0.8
P501A	40.9 $\pm$ 14.6	7.3	27.5 $\pm$ 2.4	16.2	23.2 $\pm$ 3.8	0.7	4480 $\pm$ 816.4	1.1
P574A	49.6 $\pm$ 12.5	8.9	32.5 $\pm$ 2.6	19.1	29.6 $\pm$ 3.5	0.9	5320 $\pm$ 419.8	1.3
P623A	68.4 $\pm$ 14.4	12.2	36.8 $\pm$ 2.8	21.6	37.0 $\pm$ 8.8	1.1	3302 $\pm$ 388.1	0.8

<sup>a</sup>The relative resistance (RR) values represent the relative levels of resistance of the mutants compared to that of wild-type BCRP and were calculated by dividing the IC<sub>50</sub> values of wild-type and mutant BCRP by the IC<sub>50</sub> values of the vector control. Wild-type and mutant BCRP did not confer resistance to Dox or Rho123. The IC<sub>50</sub> values shown are means  $\pm$  SD of three experiments. Differences in IC<sub>50</sub> values between wild-type and mutant BCRP are statistically significant ( $p < 0.05$  by a Student's  $t$  test). Because the expression levels of wild-type and mutant BCRP were comparable, we did not normalize the resistance data to BCRP protein expression.

Student's  $t$  test). The variation in the 5D3 fluorescence of the mutants could be caused by experimental errors and/or reflect the change in BCRP conformation caused by the mutations.


**FTC-Inhibitable Efflux Activities of Wild-Type and Mutant BCRP.** After validation of BCRP expression in Flp-In<sup>TM</sup>-293 cells, we examined the efflux activity of wild-type and mutant BCRP using a well-established flow cytometric efflux assay with three fluorescent substrates, MX, BODIPY-prazosin, and Hoechst 33342.<sup>15,18,36,37</sup> MX, BODIPY-prazosin, and Hoechst 33342 have been widely used and well-characterized as BCRP substrates.<sup>15,18,36,37</sup> They do not share any chemical and structural similarity, and therefore, the use of these compounds may help us in assessing BCRP–substrate interactions. Cells expressing wild-type BCRP showed efflux activities for all the three substrates tested (Figure 4). The

mutation of Pro<sup>392</sup> caused a significant reduction in the efflux activity of all the three substrates by 35–50% (Figure 4). In contrast, the mutation of Pro<sup>485</sup> only significantly decreased the efflux activity of BODIPY-prazosin by ~70% (Figure 4B) but had no significant effect on the efflux of MX (Figure 4A) or Hoechst 33342 (Figure 4C). Thus, the mutation of Pro<sup>485</sup> selectively affected BCRP transport activity. Mutations of other prolines had no significant effect on the efflux of the three substrates (Figure 4).

**Drug Resistance Conferred by Wild-Type and Mutant BCRP.** To further test if the mutations affect drug resistance conferred by BCRP, we determined resistance of Flp-In<sup>TM</sup>-293 cells expressing wild-type and mutant BCRP to MX, SN-38, Dox, and Rho123. As shown in Table 1, only P392A exhibited a significantly lower resistance to MX compared to that of wild-

type BCRP, which is consistent with the efflux activity data. On the other hand, both P392A and P485A showed significantly decreased resistance to SN-38 compared to that of the wild type, thus providing additional evidence that alanine substitution of Pro<sup>485</sup> changed the substrate specificity of BCRP. Mutations of other prolines had no significant effect on the resistance to MX or SN-38. We also tested the resistance to Rho123 and Dox conferred by the mutants to determine if there is a so-called “gain of function” because neither drug can be transported by wild-type BCRP. None of the mutants exhibited any significant resistance to either Dox or Rho123.

**ATPase Activities of Wild-Type and Mutant BCRP.** To examine if the changes in efflux activity of mutant BCRP are caused by alterations in its ability to hydrolyze ATP, we measured vanadate-sensitive ATPase activities of wild-type BCRP, P392A, and P485A in plasma membrane preparations. The protein expression levels of wild-type BCRP, P392A, and P485A in plasma membranes were determined by immunoblotting using mAb BXP-21 and found to be comparable after normalization to the internal plasma membrane control Na<sup>+</sup>/K<sup>+</sup>-ATPase (Figure 2C,D). Vanadate-sensitive ATPase activities attributable to wild-type and mutant BCRP were calculated by subtracting the background activities associated with the plasma membranes isolated from the vector control cells. P392A exhibited ATPase activities similar to that of wild-type BCRP. P485A exhibited a modest decrease in ATPase activity compared to that of wild-type BCRP; however, the differences were not statistically significant (Figure 5). Overall, the




**Figure 5.** Vanadate-sensitive ATPase of plasma membrane preparations containing wild-type and mutant BCRP. ATPase activities were measured using plasma membrane preparations isolated from Flp-In<sup>TM</sup>-293 cells stably expressing wild-type and mutant BCRP over a range of MgATP concentrations (0–10 mM). Shown are means  $\pm$  SD of three experiments. Because the expression levels of wild-type and mutant BCRP were comparable, we did not normalize the ATPase activity data to BCRP protein expression.

mutations of Pro<sup>392</sup> and Pro<sup>485</sup> did not substantially change ATPase activity, suggesting that the alterations in transport activity of the two proline mutants are not primarily due to the effect of the mutations on the ATP hydrolytic capability of BCRP.

#### Concentration-Dependent Effects of Prazosin and MX on 5D3 Binding to Wild-Type and Mutant BCRP.

Previous studies have demonstrated that mAb 5D3 is conformation-sensitive and can be used to monitor potential conformational changes in BCRP associated with ATP binding and hydrolysis, formation of a catalytic intermediate, or substrate and inhibitor binding.<sup>38–40</sup> Therefore, the level of binding of 5D3 to BCRP can be measured to reflect conformational changes induced by BCRP–ligand interactions.


We have previously shown that prazosin binding-induced conformational changes as monitored by measuring the level of binding of 5D3 to BCRP could be affected by single mutations, thereby leading to altered transport activity.<sup>15</sup> To investigate whether the mutations of Pro<sup>392</sup> and Pro<sup>485</sup> cause conformational changes in BCRP that affect transport activity, we measured the level of binding of 5D3 to wild-type BCRP, P392A, or P485A in the presence and absence of varying concentrations of the substrate prazosin (0–40  $\mu$ M) or MX (0–80  $\mu$ M). When cells expressing wild-type BCRP were incubated with the control phycoerythrin-conjugated IgG2b, neither prazosin at  $\leq 40$   $\mu$ M nor MX at  $\leq 80$   $\mu$ M had any effect on phycoerythrin fluorescence (data not shown), suggesting that these drugs themselves made no contribution to fluorescence detection. Also, there was no significant prazosin concentration-dependent change in 5D3-phycoerythrin fluorescence for the vector control cells (Figure 6A). In the



**Figure 6.** Concentration-dependent effects of prazosin and MX on the binding of 5D3 to wild-type BCRP, P392A, and P485A. The effects of prazosin (A) and MX (B) on the binding of 5D3 to wild-type and mutant BCRP over concentration ranges of 0–40 and 0–80  $\mu$ M, respectively, were determined using flow cytometry. Shown are means  $\pm$  SD of three experiments. Asterisks indicate statistically significant differences between wild-type BCRP and P392A or P485A ( $p < 0.05$  by a Student's  $t$  test) at various prazosin concentrations.

presence of prazosin, wild-type BCRP was associated with a concentration-dependent increase in 5D3-phycoerythrin fluorescence by up to 70%; however, there was an only slight increase in 5D3-phycoerythrin fluorescence for P392A and a slight decrease in 5D3-phycoerythrin fluorescence for P485A (Figure 6A). These results suggest that the mutations of Pro<sup>392</sup> and Pro<sup>485</sup> dramatically and differentially affect prazosin binding-induced conformational changes in BCRP. The patterns of 5D3-phycoerythrin fluorescence with MX for wild-type BCRP, P392A, and P485A were similar, but different from those with prazosin (Figure 6B). This observation implies





**Figure 7.** Schematic illustration of a molecular hinge in TM3 introduced by Pro<sup>485</sup>. A side view of a three-dimensional model of BCRP in the nucleotide-free closed apo inward-facing form is presented. The TM helices are labeled with roman numerals (I–VI). Residues Pro<sup>392</sup>, Pro<sup>480</sup>, and Pro<sup>485</sup> are colored magenta, green, and green, respectively, and denoted with arrows. Also shown on the right is an expanded view of TM3 and neighboring helices indicating a potential hinge (green) introduced by Pro<sup>485</sup>. The C-terminal half of TM3 is kinked between TM1 and TM6 in the hinged conformation and rotated closer to the interior of the drug-binding cavity of BCRP. The undistorted TM3 in the original BCRP model is colored gray.

that BCRP has a differential response to prazosin and MX binding, and the mutations of Pro<sup>392</sup> and Pro<sup>485</sup> do not seem to affect the interaction of BCRP with MX.

**A Potential Molecular Hinge in TM3 Introduced by Pro<sup>485</sup>.** According to the homology model of BCRP (Figure 7), Pro<sup>485</sup> of TM3 is located in the large drug-binding cavity. In contrast to  $\alpha$ -helices in soluble proteins, proline residues often occur within TM helices where they may induce the formation of molecular hinges.<sup>22</sup> Accordingly, Pro<sup>485</sup> being five residues from Pro<sup>480</sup> at the N-terminus of TM3 may introduce a flexible hinge in BCRP. While it is difficult to obtain atomic details of such dynamic movements of TM helices experimentally, one may explore possible TM conformations allowed by structural features of the protein using homology modeling. We tested three different conformations of TM3 in our BCRP homology model. By doing this, we found that if the alternate TM3 conformation fits into the overall structure of the original BCRP model, other parts of the original model would remain unchanged. We found that the model based on the GXXXXP motif was distorted, suggesting that the GXXXXP helix conformation cannot exist in BCRP. The model based on the 1EHK1 helix was very similar to the original BCRP model, while the model based on the 1EHK2 helix resulted in an alternative TM3 conformation compared to the original model (Figure 7, green). TM3 with a flexible hinge is oriented toward the interior of the drug-binding cavity, thus providing a potential conformation of the drug-binding cavity that coordinately brings residues involved in drug binding to optimal positions for interactions with certain substrates. This hinge would allow rearrangement of the substrate-binding sites

of BCRP, depending on the nature and geometry of substrates (e.g., size and charge) (Figure 1 of the Supporting Information). It is important to note that the model shown in Figure 7 provides just one possible alternative TM3 conformation that is allowed by the overall domain arrangement of BCRP; however, more precise and atomic analysis of this presumed hinge will only be possible by determining high-resolution structures of BCRP experimentally.

## DISCUSSION

In this study, we have analyzed the functional importance of six proline residues within or near TM helices of BCRP for drug transport (Figure 1). The prolines were substituted with alanine individually. All the mutants were well expressed and properly targeted to the plasma membrane (Figures 2 and 3), suggesting that none of the mutations had a significant impact on the proper folding and maturation of BCRP.

We found that alanine substitution of Pro<sup>485</sup> had a profound impact on the substrate selectivity of BCRP. P485A exhibited a significant decrease in the efflux activity of BODIPY-prazosin, but not of MX and Hoechst 33342, and conferred lower resistance to SN-38, but not to MX (Figure 4 and Table 1). Prior to this study, mutations of Arg<sup>482</sup> were shown to significantly affect the substrate specificity of BCRP.<sup>16,18,36,41</sup> This study provides another example that mutation of a single residue in BCRP can change its substrate specificity. On the other hand, alanine substitution of Pro<sup>392</sup> caused a significant decrease in the transport activity of all the substrates tested (Figure 4 and Table 1). Such changes in transport activity of P392A and P485A do not seem to be related to alterations in

ATP hydrolytic ability (Figure 5). No significant changes in efflux of or resistance to these substrates were observed for alanine substitutions of Pro<sup>480</sup>, Pro<sup>501</sup>, Pro<sup>574</sup>, and Pro<sup>623</sup>, suggesting that these prolines are likely not functionally important for BCRP.

To assess potential mechanisms by which the mutations of Pro<sup>392</sup> and Pro<sup>485</sup> alter the transport activity and substrate specificity of BCRP, we utilized the homology model of BCRP we previously constructed on the basis of the X-ray structure of mouse P-gp.<sup>14</sup> The homology model suggests that Pro<sup>485</sup> is located inside the putative drug-binding cavity (Figure 7). Cordes et al. analyzed sequences of 199 TM helices of membrane proteins and found that prolines are preferentially located in a terminal or central position in TM helices.<sup>22</sup> In the terminal position, prolines may serve as helix-breaking residues. In a central region, prolines may have a possible structural and/or functional role via introduction of a hinge (a region of possible flexibility) in the middle of a TM helix.<sup>21,22,42,43</sup> This is exactly what we see in TM3 of BCRP. Pro<sup>485</sup> is located in the central region of TM3, which is five residues from the starting residue, Pro<sup>480</sup> (Figure 1A). Pro<sup>485</sup> therefore may introduce a structurally flexible hinge into the middle of TM3. From the structural point of view, such a hinge may bring in a curved structure of TM3 that could make the drug-binding cavity more structurally dynamic. We have constructed a homology model of the hinge to illustrate this concept (Figure 7). The motion of the flexible hinge may be dependent on the chemical or physical nature of substrates such as size or charge. Indeed, the chemical structure and molecular volume of the substrates tested in this study are quite diverse (Figure 1 of the Supporting Information). We believe that this could be one of the reasons why BCRP can accommodate and transport structurally and chemically diverse substrates. Thus, Pro<sup>485</sup> may play an important role in drug binding by introducing a flexible hinge to make the drug-binding cavity optimal for interactions with certain substrates. Alanine substitution of Pro<sup>485</sup> would eliminate the helical distortion of TM3 and the flexibility and influence the helical packing with neighboring TM helices, thereby affecting transport activity for some substrates. The results of this study suggest that alanine substitution of Pro<sup>485</sup> does not affect binding or transport for MX and Hoechst 33342 but weakens binding and transport for prazosin and SN-38.

Clark et al. performed equilibrium and kinetic drug binding studies with BCRP and showed that MX and Hoechst 33322 may share similar binding sites, which were distinct from that of prazosin.<sup>44</sup> The results of this study appear to be consistent with the direct drug binding data based upon the assumption that the molecular hinge introduced by Pro<sup>485</sup> may differentially affect interaction of BCRP with some substrates (e.g., prazosin and SN-38), but not others (e.g., MX and Hoechst 33342) possibly because of different binding sites or different binding regions within the same site. Although it is generally believed that the MSD participates in drug binding, the exact location of drug binding sites in BCRP remains to be determined. The functional importance of Pro<sup>223</sup> and Pro<sup>866</sup> in P-gp has also been demonstrated.<sup>27</sup> Pro<sup>223</sup> and Pro<sup>866</sup> are located in the central region of TM4 and TM10 of P-gp, respectively. Likewise, alanine substitution of Pro<sup>223</sup> or Pro<sup>866</sup> significantly decreased the efflux activity of colchicine but had no effect on the efflux activity of vinblastine, suggesting that colchicine and vinblastine likely bind to different sites or different regions within the same binding site.

With regard to Pro<sup>392</sup>, our homology model suggests that it is located in the linker region between the MSD and the NBD (Figure 7). This led us to hypothesize that the mutation of Pro<sup>392</sup> affects the communication between the two domains that is essential for BCRP function. This is consistent with previous studies showing the functional importance of the linker region. For example, Asn<sup>387</sup> and Gln<sup>398</sup> in the linker region were replaced with alanine, leading to a significant decrease in BCRP activity.<sup>15</sup>

On the basis of the membrane topology of BCRP we recently determined,<sup>13</sup> Pro<sup>480</sup> is predicted to be at the N-terminal end of TM3 and thus may play a role in helix breaking. Pro<sup>574</sup> is predicted to be in the middle of TM5. However, mutations of either proline showed no significant effect on BCRP function. It is important to note that Pro<sup>485</sup> is only three residues from Arg<sup>482</sup> (both residues are within TM3), of which mutations have been shown to significantly alter the substrate specificity of BCRP.<sup>16,18,36,41</sup> Arg<sup>482</sup> is possibly part of the molecular hinge introduced by Pro<sup>485</sup>, and both residues may contribute to the broad substrate specificity of BCRP. However, how exactly Arg<sup>482</sup> and Pro<sup>485</sup> work together to determine substrate specificity is not clear. Collectively, TM3 is very likely to be involved in drug binding and transport, and the role of TM3 in determining transport activity and substrate specificity of BCRP warrants further investigation.

We have previously demonstrated substrate binding-induced conformational changes in BCRP by analyzing two-dimensional crystals with and without MX.<sup>14</sup> Such conformational changes can be monitored by measuring 5D3 binding. mAb 5D3 binds to a highly specific epitope in an extracellular loop of BCRP and is conformation-sensitive. Therefore, to further illustrate if mutations of Pro<sup>392</sup> and Pro<sup>485</sup> affect BCRP–substrate interactions by perturbing substrate binding-induced conformational changes and thus transport activity and substrate specificity, we analyzed binding of 5D3 to wild-type and mutant BCRP in the presence and absence of prazosin or MX. First, wild-type BCRP responded very differently to 5D3 binding in the presence of prazosin or MX (Figure 6), again suggesting differential interactions between BCRP and the two substrates. Second, the responses of wild-type BCRP, P392A, and P485A to 5D3 binding in the presence of prazosin were significantly different from each other (Figure 6A). However, there was no difference between wild-type BCRP, P392A, and P485A in response to 5D3 binding in the presence of MX (Figure 6B). This further suggests that the mutations of Pro<sup>392</sup> and Pro<sup>485</sup> induce conformational changes in BCRP that differentially affect BCRP–substrate interactions, and thus, the two prolines play different functional roles in BCRP activity. Such effects are substrate-dependent (i.e., due to different binding sites).

In summary, we have demonstrated the importance of Pro<sup>392</sup> in the overall transport activity and Pro<sup>485</sup> in the substrate selectivity of BCRP. We also provided functional evidence that Pro<sup>485</sup> in TM3 may introduce flexible hinges that allow BCRP to accommodate a wide spectrum of substrates, whereas Pro<sup>392</sup> may play a role in the communication between the MSD and the NBD during the transport cycle.

## ■ ASSOCIATED CONTENT

### ● Supporting Information

Chemical structure, molecular volume, and cLogP value of the substrates used in this study. This material is available free of charge via the Internet at <http://pubs.acs.org>.



## AUTHOR INFORMATION

### Corresponding Author

\*Department of Pharmaceutics, School of Pharmacy, University of Washington, Room H272F, Health Sciences Building, Box 357610, Seattle, WA 98195-7610. Telephone: (206) 685-0355. Fax: (206) 543-3204. E-mail: qmao@u.washington.edu.

### Funding

This work was supported by National Institutes of Health Grant GM073715.

## ACKNOWLEDGMENTS

We thank Dr. Susan E. Bates (National Cancer Institute) for providing the pcDNA3.1 expression vector containing full-length human wild-type BCRP cDNA. We also acknowledge the Drug Synthesis & Chemistry Branch, National Cancer Institute, for providing FTC. We greatly acknowledge Drs. Haichuan Duan and Joanne Wang (Department of Pharmaceutics, University of Washington) for providing the pcDNA5/FRT expression vector.

## ABBREVIATIONS

BCRP, breast cancer resistance protein; P-gp, P-glycoprotein; ABC, ATP-binding cassette; ABCG2, ATP-binding cassette G2; NBD, nucleotide-binding domain; MSD, membrane-spanning domain; TM, transmembrane; WT, wild-type; MX, mitoxantrone; Dox, doxorubicin; Rho123, rhodamine 123; FTC, fumitremorgin C; DMSO, dimethyl sulfoxide; DMEM, Dulbecco's modified Eagle's minimal essential medium; FBS, fetal bovine serum; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; LB, Luria-Bertani; SDS, sodium dodecyl sulfate; mAb, monoclonal antibody; DAPI, 4',6-diamidino-2-phenylindole; SN-38, 7-ethyl-10-hydroxycamptothecin; BODIPY, boron-dipyrromethene; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDB, Protein Data Bank; SD, standard deviation.

## REFERENCES

- (1) Robey, R. W., To, K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., and Bates, S. E. (2009) ABCG2: A perspective. *Adv. Drug Delivery Rev.* 61, 3–13.
- (2) Mao, Q., and Unadkat, J. D. (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. *AAPS J.* 7, E118–E133.
- (3) Sarkadi, B., Homolya, L., Szakacs, G., and Varadi, A. (2006) Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoinnity defense system. *Physiol. Rev.* 86, 1179–1236.
- (4) Ishikawa, T., and Nakagawa, H. (2009) Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. *J. Exp. Ther. Oncol.* 8, 5–24.
- (5) Ni, Z., Bikadi, Z., Rosenberg, M. F., and Mao, Q. (2010) Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). *Curr. Drug Metab.* 11, 603–617.
- (6) Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., and Sorrentino, B. P. (2002) Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 99, 12339–12344.
- (7) Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J., and Schellens, J. H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res.* 61, 3458–3464.

- (8) Cooray, H. C., Blackmore, C. G., Maskell, L., and Barrand, M. A. (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. *Neuroreport* 13, 2059–2063.
- (9) Xu, J., Peng, H., Chen, Q., Liu, Y., Dong, Z., and Zhang, J. T. (2007) Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. *Cancer Res.* 67, 4373–4381.
- (10) Ni, Z., Mark, M. E., Cai, X., and Mao, Q. (2010) Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. *Int. J. Biochem. Mol. Biol.* 1, 1–11.
- (11) Liu, Y., Yang, Y., Qi, J., Peng, H., and Zhang, J. T. (2008) Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. *J. Pharmacol. Exp. Ther.* 326, 33–40.
- (12) McDevitt, C. A., Collins, R. F., Conway, M., Modok, S., Storm, J., Kerr, I. D., Ford, R. C., and Callaghan, R. (2006) Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. *Structure* 14, 1623–1632.
- (13) Wang, H., Lee, E. W., Cai, X., Ni, Z., Zhou, L., and Mao, Q. (2008) Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. *Biochemistry* 47, 13778–13787.
- (14) Rosenberg, M. F., Bikadi, Z., Chan, J., Liu, X., Ni, Z., Cai, X., Ford, R. C., and Mao, Q. (2010) The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. *Structure* 18, 482–493.
- (15) Ni, Z., Bikadi, Z., Cai, X., Rosenberg, M. F., and Mao, Q. (2010) Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): Identification of polar residues important for drug transport. *Am. J. Physiol.* 299, C1100–C1109.
- (16) Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M., and Bates, S. E. (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. *Cancer Res.* 61, 6635–6639.
- (17) Cai, X., Bikadi, Z., Ni, Z., Lee, E. W., Wang, H., Rosenberg, M. F., and Mao, Q. (2010) Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport. *J. Pharmacol. Exp. Ther.* 333, 670–681.
- (18) Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T. A., Runge, S., Risbood, M., Poruchynsky, M. S., and Bates, S. E. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. *Br. J. Cancer* 89, 1971–1978.
- (19) Chen, Z. S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q., Sugimoto, Y., Ross, D. D., Bates, S. E., and Kruh, G. D. (2003) Transport of methotrexate, methotrexate polyglutamates, and 17 $\beta$ -estradiol 17-( $\beta$ -D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. *Cancer Res.* 63, 4048–4054.
- (20) Polgar, O., Ierano, C., Tamaki, A., Stanley, B., Ward, Y., Xia, D., Tarasova, N., Robey, R. W., and Bates, S. E. (2010) Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. *Biochemistry* 49, 2235–2245.
- (21) Williams, K. A., and Deber, C. M. (1991) Proline residues in transmembrane helices: Structural or dynamic role? *Biochemistry* 30, 8919–8923.
- (22) Cordes, F. S., Bright, J. N., and Sansom, M. S. (2002) Proline-induced distortions of transmembrane helices. *J. Mol. Biol.* 323, 951–960.
- (23) von Heijne, G. (1991) Proline kinks in transmembrane  $\alpha$ -helices. *J. Mol. Biol.* 218, 499–503.
- (24) Woolfson, D. N., and Williams, D. H. (1990) The influence of proline residues on  $\alpha$ -helical structure. *FEBS Lett.* 277, 185–188.
- (25) Vilsen, B., Andersen, J. P., Clarke, D. M., and MacLennan, D. H. (1989) Functional consequences of proline mutations in the cytoplasmic and transmembrane sectors of the Ca<sup>2+</sup>-ATPase of sarcoplasmic reticulum. *J. Biol. Chem.* 264, 21024–21030.
- (26) Rothschild, K. J., He, Y. W., Mogi, T., Marti, T., Stern, L. J., and Khorana, H. G. (1990) Vibrational spectroscopy of bacteriorhodopsin

mutants: Evidence for the interaction of proline-186 with the retinylidene chromophore. *Biochemistry* 29, 5954–5960.

(27) Loo, T. W., and Clarke, D. M. (1993) Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. *J. Biol. Chem.* 268, 3143–3149.

(28) Koike, K., Conseil, G., Leslie, E. M., Deeley, R. G., and Cole, S. P. (2004) Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. *J. Biol. Chem.* 279, 12325–12336.

(29) Ito, K., Weigl, K. E., Deeley, R. G., and Cole, S. P. (2003) Mutation of proline residues in the NH<sub>2</sub>-terminal region of the multidrug resistance protein, MRP1 (ABCC1): Effects on protein expression, membrane localization, and transport function. *Biochim. Biophys. Acta* 1615, 103–114.

(30) Koike, K., Conseil, G., Leslie, E. M., Deeley, R. G., and Cole, S. P. (2004) Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. *J. Biol. Chem.* 279, 12325–12336.

(31) Letourneau, I. J., Nakajima, A., Deeley, R. G., and Cole, S. P. (2008) Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. *Biochem. Pharmacol.* 75, 1659–1669.

(32) Soulimane, T., Buse, G., Bourenkov, G. P., Bartunik, H. D., Huber, R., and Than, M. E. (2000) Structure and mechanism of the aberrant ba<sub>3</sub>-cytochrome c oxidase from *Thermus thermophilus*. *EMBO J.* 19, 1766–1776.

(33) Chang, C. H., el-Kabbani, O., Tiede, D., Norris, J., and Schiffer, M. (1991) Structure of the membrane-bound protein photosynthetic reaction center from *Rhodobacter sphaeroides*. *Biochemistry* 30, 5352–5360.

(34) Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* 234, 779–815.

(35) Pace, C. N., and Scholtz, J. M. (1998) A helix propensity scale based on experimental studies of peptides and proteins. *Biophys. J.* 75, 422–427.

(36) Ozvegy-Laczka, C., Koblos, G., Sarkadi, B., and Varadi, A. (2005) Single amino acid (482) variants of the ABCG2 multidrug transporter: Major differences in transport capacity and substrate recognition. *Biochim. Biophys. Acta* 1668, 53–63.

(37) Robey, R. W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J. T., Litman, T., and Bates, S. E. (2001) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). *Biochim. Biophys. Acta* 1512, 171–182.

(38) Ozvegy-Laczka, C., Varady, G., Koblos, G., Ujhelly, O., Cervenak, J., Schuetz, J. D., Sorrentino, B. P., Koomen, G. J., Varadi, A., Nemet, K., and Sarkadi, B. (2005) Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. *J. Biol. Chem.* 280, 4219–4227.

(39) Shukla, S., Robey, R. W., Bates, S. E., and Ambudkar, S. V. (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. *Drug Metab. Dispos.* 37, 359–365.

(40) Ozvegy-Laczka, C., Laczko, R., Hegedus, C., Litman, T., Varady, G., Goda, K., Hegedus, T., Dokholyan, N. V., Sorrentino, B. P., Varadi, A., and Sarkadi, B. (2008) Interaction with the SD3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. *J. Biol. Chem.* 283, 26059–26070.

(41) Miwa, M., Tsukahara, S., Ishikawa, E., Asada, S., Imai, Y., and Sugimoto, Y. (2003) Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. *Int. J. Cancer* 107, 757–763.

(42) Govaerts, C., Blanpain, C., Deupi, X., Ballet, S., Ballesteros, J. A., Wodak, S. J., Vassart, G., Pardo, L., and Parmentier, M. (2001) The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. *J. Biol. Chem.* 276, 13217–13225.

(43) Sansom, M. S., and Weinstein, H. (2000) Hinges, swivels and switches: The role of prolines in signalling via transmembrane  $\alpha$ -helices. *Trends Pharmacol. Sci.* 21, 445–451.

(44) Clark, R., Kerr, I. D., and Callaghan, R. (2006) Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. *Br. J. Pharmacol.* 149, 506–515.